

=> d his

(FILE 'HOME' ENTERED AT 09:27:43 ON 03 APR 2000)

FILE 'MEDLINE' ENTERED AT 09:27:55 ON 03 APR 2000

L1 562 S PREDNISONE AND RHEUMATOID (W) ARTHRITIS  
L2 0 S L1 AND RETICULOSE  
L3 302 S L1 AND TREAT?

L3 ANSWER 282 OF 302 MEDLINE  
 AN 75210616 MEDLINE  
 DN 75210616  
 TI Therapeutic effectiveness of paracetamol in **rheumatoid arthritis**.  
 AU Lee P; Watson M; Webb J; Anderson J; Buchanan W  
 SO INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND BIOPHARMACY, (1975 Jan)  
 11 (1) 68-75.  
 Journal code: GR1.  
 CY GERMANY, WEST: Germany, Federal Republic of  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LA English  
 FS Priority Journals  
 EM 197512  
 AB A single-blind, non-crossover study of the effectiveness of paracetamol, compared with aspirin and indomethacin has been carried out in 143 patients suffering from **rheumatoid arthritis**. Subjective indices have been employed, and the validity of the present method is discussed. The results of the trial have also been compared with those of a previous study (of **prednisone**, aspirin and placebo). Paracetamol was not significantly different from placebo, either in terms of pain relief or patient satisfaction rating. **Prednisone** and indomethacin were significantly better than paracetamol in respect to both parameters, but aspirin was not. On the basis of these results, the frequent prescription of paracetamol as the main therapeutic agent in the **treatment of rheumatoid arthritis** is not justified.

L3 ANSWER 263 OF 302 MEDLINE  
 AN 79186317 MEDLINE  
 DN 79186317  
 TI Effects of gold, dapsone, and **prednisone** on serum C-reactive protein and haptoglobin and the erythrocyte sedimentation rate in **rheumatoid arthritis**.  
 AU McConkey B; Davies P; Crockson R A; Crockson A P; Butler M; Constable T J;  
 J; Amos R S  
 SO ANNALS OF THE RHEUMATIC DISEASES, (1979 Apr) 38 (2) 141-4.  
 Journal code: 62W. ISSN: 0003-4967.  
 CY ENGLAND: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 197909  
 AB Sequential measurements of serum C-reactive protein (CRP), serum haptoglobin (Hp), and erythrocyte sedimentation rate (ESR) were made in 209 patients with **rheumatoid arthritis** (RA); 78 of them were **treated** with gold, 71 with dapsone, and 60 with **prednisone**. The results were expressed as proportional changes in the measurements at 28-day intervals after **treatment** began. The period of study was 140 days. During **treatment** with gold and dapsone there were statistically significant gradual and progressive falls of similar magnitude in serum CRP and ESR. During **treatment** with **prednisone** serum CRP and ESR fell abruptly by 28 days and thereafter altered little. At 140 days **prednisone** had had the largest proportional effect on both measurements. During gold **treatment** the fall in serum Hp was similar to that of the ESR. In contrast, **prednisone** had little effect on Hp levels despite large falls in serum CRP and the ESR. Either **prednisone** stimulates Hp synthesis or the divergence is an expression of the difference in type of effect between gold and **prednisone** on RA. The effect of dapsone on serum Hp was large and progressive; it partly reflects haemolysis and, since the haemolysis was not progressive, partly improvement in the RA. The results show the relative efficacy of the drugs and suggest that dapsone may be a useful alternative **treatment**

L3 ANSWER 261 OF 302 MEDLINE  
 AN 79222557 MEDLINE  
 DN 79222557  
 TI Current trends in the **treatment** of **rheumatoid arthritis** in general practice.  
 AU Lee P; Tan L J  
 SO NEW ZEALAND MEDICAL JOURNAL, (1979 Mar 14) 89 (631) 165-7.  
 Journal code: OBQ. ISSN: 0028-8446.  
 CY New Zealand  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 197911  
 AB Questionnaires were sent to 180 randomly selected general medical practitioners in the Auckland area, to determine the source of prescribing information and current drug prescribing pattern in general practice, for the **treatment** of **rheumatoid arthritis**. Medical journals were the main current source but postgraduate seminars and lectures were the preferred source of prescribing information.  
 Aspirin remains the drug of first choice in the **treatment** of **rheumatoid arthritis** and along with indomethacin, phenylbutazone and **prednisone** (10 mg daily), considered to be more effective than the newer propionic acid derivatives. Enteric coated aspirin was preferred in the patient with an active peptic ulcer. Almost all of the replying doctors, endeavoured to give their patients an explanation as to the underlying nature of their disease and **treatment**, but had little confidence that they would comply with the therapeutic instructions.

L3 ANSWER 236 OF 302 MEDLINE  
 AN 84064623 MEDLINE  
 DN 84064623  
 TI Low dose **prednisone** therapy in **rheumatoid arthritis**: a double blind study.  
 AU Harris E D Jr; Emkey R D; Nichols J E; Newberg A  
 NC P60 AM20641 (NIADDK)  
 SO JOURNAL OF RHEUMATOLOGY, (1983 Oct) 10 (5) 713-21.  
 Journal code: JWX. ISSN: 0315-162X.  
 CY Canada  
 DT (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 198403  
 AB **Prednisone**, 5 mg taken each morning, was added to other drugs in 18 patients with **rheumatoid arthritis**. Sixteen patients were given a placebo in this double blind study. After 24 weeks, all patients were given the placebo. Slight functional improvement was noted in the **prednisone** group during the 24-week period, but deterioration after switching to placebo was sustained for at least 8 weeks. Progression of hand erosions occurred in 1 **prednisone-treated** patient, and in 4 controls. An asymptomatic vertebral spine compression fracture developed in 2 patients given **prednisone**; this was the only toxicity noted possibly due to this therapy. Minimal dose **prednisone** may be useful as "bridge" therapy between nonsteroidal antiinflammatory therapy and use of disease-modifying drugs.

	L #	Hits	Search Text	DBs	Time Stamp
1	L1	429	prednisone and rheumatoid and treat\$4	USPAT	2000/04/0 3 09:18
2	L2	36	1 and prednisone.clm.	USPAT	2000/04/0 3 09:24
3	L3	0	1 and (reticulose or product adj r)	USPAT	2000/04/0 3 09:24

	Document ID	Issue Date	Pages	Title
1	US 6020356 A	20000201	4	Pharmaceutical composition for the treatment of autoimmune diseases
2	US 5817305 A	19981006	17	Anti-inflammatory compositions and methods
3	US 5811446 A	19980922	10	Prophylactic and therapeutic methods for ocular degenerative diseases  and inflammations and histidine compositions therefor
4	US 5792476 A	19980811	4	Sustained release glucocorticoid pharmaceutical composition
5	US 5753218 A	19980519	8	Method for treating inflammation
6	US 5043165 A	19910827	24	Novel liposome composition for sustained release of steroidal drugs
7	US 4743596 A	19880510	4	Anti-arthritic preparation
8	US 4448774 A	19840515	4	Steroid formulation
9	US 4312865 A	19820126	6	Medication having penetration through cutaneous surfaces into articular  and muscular areas
10	US 4011316 A	19770308	6	Cyclohexa-2,5-diene-1-thi ones